2 “Strong Buy” stocks of around $ 10 with triple-digit upside potential
The S&P 500 hit a new high on Friday, and at least one strategist believes we are at the start of a new bull market. In a writing from LPL Financial, chief market strategist Ryan Detrick noted several historical market points that indicate lasting gains are ahead. Its main points are first quarter returns and the extent of the current stock rally. Regarding yields, Detrick points out that the S&P 500 gained nearly 6% in the first quarter – and that the 6% level was an accurate indicator of short-term trends. “Since 1950, when the S&P 500 rose 5% to 10% in the first quarter, the rest of the year has gained another 12.4% on average and has been higher 86.7% of the time,” noted the strategist. The payoffs can be more important, however. Detrick tells us the current rally is attracting participation from a range of different market sectors – stocks are up almost everywhere, with 95% of the S&P 500 components breaking their 200-day move Detrick shows this trend prevailed in December 2003 and September 2009 – and that these two months marked the start of a multi-year bullish period. The key now, to thrive in the environment to come, is to find stocks that are ready to win. Using the TipRanks database, we found two stocks that fit a profile: They have a consensus analyst rating from Strong Buy, have trading prices of around $ 10 per share, and best of all, they could offer huge growth prospects. Table. We’re talking about triple-digit upside potential here. F-star Therapeutics (FSTX) First, F-star Therapeutics, a clinical stage biopharmaceutical company specializing in immuno-oncology. The company’s pipeline includes tetravalent mAb2 bispecific antibodies, a proprietary technology that F-star says will address the challenges of immuno-oncology therapies. According to the company, the antibodies are “designed to treat multiple pathways of immune evasion,” thus enhancing their effect over currently available therapies. F-star has a development pipeline comprising both proprietary programs and partnership programs. FS118, the most advanced drug candidate, has completed a phase 1 clinical trial, which has shown positive results, with signs of clinical activity linked to its new mechanism of action. A proof of concept trial is currently underway with patients with PD-1 resistant head and neck cancers. In addition, the European Patent Office granted in January of this year a patent on the FS118 molecule, with an expiration date in 2037. The next most advanced program, FS222, is described as a “potentially bispecific antibody”. best-in-class targeting CD137. and PD-L1. The drug candidate is entering a phase 1 trial, with the first patient receiving a dose last January. The trial will assess safety, tolerability and the first signs of efficacy. The patient base will be adults, with a diagnosis of advanced malignancies. Last November, F-star went public on NASDAQ through a SPAC merger. The merger was completed and the symbol FSTX began trading on November 23; since then the title has gained an impressive 151%. Describing the company as “a potential north star of bispecific antibody engineering,” Hartaj Singh, Oppenheimer’s 5-star analyst, believes that there are still many benefits for FSTX. “We believe that FSTX filters well among the various bispecific antibody (BsAbs) platforms that have evolved rapidly over the past two years (our white paper), given the capability of the company’s platform. to take advantage of the three key characteristics of BsAbs: conditionality / cross-linking / clustering across its molecules “A tetravalent binding independent of the Fc-gamma receptor (FcγR) and generates high value uncorrelated oncological assets,” said Singh. The analyst added, “In our opinion, the story of FSTX ticked the boxes for: (1) a targeted oncology biomarker-driven approach identifying a subset of the patient population that allows for expedited approval; (2) improved risk / benefit profile with low immunogenicity / high affinity target engagement / no hook effect / etc .; (3) unveiling of a new target synergy inaccessible by a combination of mAbs; and (4) experienced / execution oriented management. “In keeping with his bullish outlook, Sing credits FSTX with an outperformance (i.e. a buy) and sets a price target of $ 30. His target implies a potential upside of 200% year on year. look at Singh’s track record, click here) Singh is not outlier on this one The four most recent F-star reviews are to “buy,” which makes the analyst consensus rating a strong buy. The stocks are trading at $ 9.98 and their $ 33.5 The average price target suggests a 235% rise for the coming year. (See FSTX market analysis on TipRanks) Veru (VERU) Veru, The next company we’re looking at, is another oncology-focused biopharmaceutical company.New medical treatments for prostate and breast cancer, two high-profile malignancies. Veru’s lead candidate, VERU-111, is on the line. study as a treatment for both prostate cancer and breast cancer, and is even being tested in t ant that potential treatment for COVID-19. The drug candidate has entered a phase 2 clinical trial in the treatment of metastatic castration and androgen receptors targeting agent-resistant prostate cancer. The trial is fully registered and ongoing, and no serious adverse reactions have been reported. Efficacy results include decreases in PSA as well as objective and lasting tumor responses. The second application of VERU-111 is in the treatment of triple negative metastatic breast cancer (TNBC), and the aggressive form of the disease which accounts for approximately 15% of all breast cancer cases. TNBC patients may be candidates for treatment with VERU-111, and preclinical studies have shown that the drug candidate can significantly inhibit the proliferation, migration, metastasis and invasion of TNBC tumor cells that have developed resistance to TNBC. taxane treatment. Veru will meet with the FDA in 1H21 to discuss trial designs for a Phase 2b clinical study of this medical avenue, which is scheduled to begin in 2H21. VERU-111 has also completed an accelerated Phase 2 clinical study of its efficacy for the treatment of inpatients with COVID-19 and at high risk of acute respiratory distress syndrome (ARDS). The FDA agreed to move the study to a phase 3 trial, to confirm the risk / benefit analysis. Clinical results should start to arrive during 4Q21. Another drug developed by the company for the treatment of breast cancer is enobosarm, a selective androgen receptor agonist, which could potentially treat AR + / HR + breast cancers resistant to current endocrine therapy. The company plans to start a phase 3 study for enobosarm in the coming months, with data expected in 2H23. In addition, the company submitted its NDA for tadalafil, a new drug for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. The PDUFA date is set for December 2021 and, if approved, Veru will market the drug through third-party telemedicine partners. The company also offers an FDA approved product FC2, a female internal condom for the prevention of unwanted pregnancy as well as disease prevention. In the fourth quarter, the company saw 50% growth in FC2 prescription sales, with revenue climbing to $ 9.1 million from $ 6.1 million in 4Q20. The multi-apps caught the attention of Jeffries analyst Chris Howerton, who values VERU stocks with a price target of $ 19. This figure suggests a potential upside of 104% from the current share price of $ 9.32. (To see Howerton’s review, click here) “We love top cancer programs,” 111 for prostate cancer and enobasarm for breast cancer, which will enter Ph3 imminently, positive results that could unlock cumulative, peak, and unadjusted sales of> $ 3 billion. After a recent change in strategy, non-core / legacy assets are expected to be divested, which could provide non-dilutive NT capital, ”Howerton noted. The analyst continued, “We are looking at other pipeline programs and non-core business units, such as their female condom (FC2), as options to buy at our fundamental valuation. Historically, Veru was built as a prostate-focused business, with a supporting sexual health business to “ pay the bills. ” As a result, there are some idiosyncratic characteristics of their pipeline that could provide an incremental rise, in the short to medium term, but we do not consider a long term valuation important. The rest of Wall Street echoes Howerton’s bullish play, as TipRanks analyzes portray VERU as a strong buy. Out of 5 analysts followed in the past 3 months, all 5 are bullish on the stock. yield around 154%, the target consensus price of the stock is $ 23.60. (See VERU stock analysis on TipRanks) attractive valuations, visit the best stocks to buy from TipRanks, a newly launched tool that brings together all information about the TipRanks stocks. Disclaimer: The opinions expressed in this article are solely those of the featured analysts Content is intended for use at informational purposes only.It is very important to do your own analysis before making any investment.